
    
      The secondary objectives are to evaluate:

      A. The potential and observed clinical impact of the implementation of collaborative
      pharmaceutical care.

      B. The acceptance rate of pharmaceutical interventions during collaborative pharmaceutical
      care.

      C. Avoidable costs related to the consumption of care generated by the occurrence of serious
      adverse drug reactions.

      D. The satisfaction of health professionals concerning the transfer of information on the
      patient's drug therapy carried out as part of collaborative pharmaceutical care.
    
  